BCR activated CLL B cells use both CR3 (CD11b/CD18) and CR4 (CD11c/CD18) for adhesion while CR4 has a dominant role in migration towards SDF-1

• Published in: PloS one Vol. 16; no. 7; p. e0254853
• Main Authors: Nagy-Baló, Zsuzsa, Kiss, Richárd, Demeter, Judit, Bödör, Csaba, Bajtay, Zsuzsa, Erdei, Anna
• Format: Journal Article
• Language: English
• Published: San Francisco Public Library of Science 20.07.2021; Public Library of Science (PLoS)
• Subjects: Adhesion; Biology and Life Sciences; Bone marrow; CD11b antigen; CD11c antigen; CD18 antigen; Cell migration; Chronic lymphocytic leukemia; Fibrinogen; Flow cytometry; Immunology; Leukemia; Lymphocytes; Lymphocytes B; Lymphoma; Medical prognosis; Medical research; Medicine and Health Sciences; Pathogenesis; Research and Analysis Methods; SDF-1 protein; Hungary
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0254853

Chronic lymphocytic leukaemia (CLL) is the most common leukaemia in the western world. In previous studies, various proportion of patients was found to carry CD11b + or CD11c + B cells whose presence was an unfavourable prognostic factor. The exact mechanism however, how these receptors contribute to the pathogenesis of CLL has not been revealed so far. Here we analysed the role of CD11b and CD11c on B cells of CLL patients in the adhesion to fibrinogen and in the migration towards stromal cell derived factor-1 (SDF-1) and studied the role of CR4 in the adherence of the CD11c + B cell line BJAB. We observed that both CR3 and CR4 mediate adhesion of the malignant B cells. Moreover, we found, that CR4 was strongly involved in the migration of the leukemic cells towards the chemoattractant SDF-1. Our data suggest that CR3 and CR4 are not only passive markers on CLL B cells, but they might contribute to the progression of the disease. Since the role of SDF-1 is prominent in the migration of CLL cells into the bone marrow where their survival is supported, our findings help to understand how the presence of CD11c on leukemic B cells can worsen the prognosis of chronic lymphocytic leukaemia.